Stemgent Starts Scottish Protein Tools Venture | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Stem cell products developer Stemgent said today that it has started a new business in Scotland that will develop reagents and kits and offer services for use in studying the ubiquitin proteasome pathway (UPP) for drug research.

Stemgent, which has operations in Boston and San Diego, will invest roughly $4.5 million over three years in the new venture, which is based in Dundee.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.